

## AUTHOR CONTRIBUTION FORM

| Title | The optimized anti-CD20 monoclonal antibody ublituximab bypasses <br> natural killer phenotype features in Waldenstrôm macroglobulinemia |
| :--- | :--- |
| First author | Magali Le Garff-Tavernier |

According to the International Committee of Medical Journal Editors (ICMJE) (http://www.icmje.org/ethical 1author.html):
"Authorship credit should be based on: 1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; and 3) final approval of the version to be published. Authors should meet conditions 1, 2 and 3. Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship".

The responsible author of this manuscript confirms that all persons designated as authors qualify for authorship, and that each author has participated sufficiently in the work to take public responsibility for appropriate portions of the content.

Responsible author (author responsible for the integrity of the work as a whole)
Name: Magali Le Garff-Tavernier
Institute: AP-HP
e-mail: magali.legarff@psl.aphp.fr

## Author contributions

Please describe the contributions of each author, indicating who was responsible for each part of the study and the preparation of the manuscript (collection of data, experiments, data analysis, generation of figures, interpretation of data, preparation of the text, etc.) :

M Le Garff-Tavernier, H Merle-Beral and V Vieillard were the principal investigators and take primary responsibility for the paper, analyzed the data, and wrote the paper;
C de Romeuf and R Urbain provided anti-CD20 mAb reagents and participated to the design of the study;
N Azar, D Roos-Weil, and V Leblond recruited the patients;
M Le Garff-Tavernier, L Herbi and P Bonnemye performed the laboratory work for this study;
All authors critically read and approved the manuscript.
$\square$

